Innovating Pharmaceutical Therapies
Pioneering the world’s first prescription CBD for social anxiety disorder.
Extraordinary Leadership. Unparalleled Experience.
EmpowerPharm is conducting clinical studies using cannabidiol (CBD) for prescription medicines to treat social anxiety disorder.
EmpowerPharm Inc. is a Canadian owned pharmaceutical company dedicated to creating a company driven for social impact. Leveraging our diverse expertise as industry leaders, we specialize in the research, development, manufacturing, and commercialization of medicines with novel formulations in our state-of-the-art GMP pharmaceutical facility located in Burlington, Canada.
Our Mission: We are empowered to develop and commercialize products through improved drug delivery technology that will improve patient therapeutic outcomes and quality of life
CurrentNews
EmpowerPharm Inc. is delighted to announce the outcome of their Phase 2 clinical trial assessing Cannabidiol (CBD) drug product for Social Anxiety Disorder (SAD)
EmpowerPharm Inc. https://empowerpharm.ca/ is delighted to announce the outcome of their Phase 2 clinical trial assessing the dose finding, efficacy, safety, and tolerability of Cannabidiol ...
Read More →
EMPOWERPHARM AWAITS PHASE II CLINICAL TRIAL ON GROUND BREAKING TREATMENT TO MANAGE SOCIAL ANXIETY DISORDER
Burlington, ON March 11, 2024 - EmpowerPharm Inc. is delighted to announce that the final participant has completed their treatment in the Phase II clinical ...
Read More →
EmpowerPharm Patent- PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF CANNABINOIDS was published today.
EmpowerPharm® a clinical stage pharmaceutical company specializing in cannabinoid-based drug development of prescription products. These products target therapeutic indications where ...
Read More →
EmpowerPharm Inc. is delighted to announce the outcome of their Phase 2 clinical trial assessing Cannabidiol (CBD) drug product for Social Anxiety Disorder (SAD)
EmpowerPharm Inc. https://empowerpharm.ca/ is delighted to announce the outcome of their Phase 2 clinical trial assessing the dose finding, efficacy, safety, and tolerability of Cannabidiol ...
Read More →
EMPOWERPHARM AWAITS PHASE II CLINICAL TRIAL ON GROUND BREAKING TREATMENT TO MANAGE SOCIAL ANXIETY DISORDER
Burlington, ON March 11, 2024 - EmpowerPharm Inc. is delighted to announce that the final participant has completed their treatment in the Phase II clinical ...
Read More →